BACKGROUND: The frequency of HIV dementia in a recent study of HIV+ individuals at the Infectious Disease Institute in Kampala, Uganda, was 31%. Coformulated generic drugs, which include stavudine, are the most common regimens to treat HIV infection in Uganda and many other parts of Africa. OBJECTIVE: To evaluate the benefits and risks of stavudine-based highly active antiretroviral therapy (HAART) for HIV-associated cognitive impairment and distal sensory neuropathy. The study compared neuropsychological performance changes in HIV+ individuals initiating HAART for 6 months and HIV- individuals receiving no treatment for 6 months. The risk of antiretroviral toxic neuropathy as a result of the initiation of stavudine-based HAART was also examined. METHODS: At baseline, 102 HIV+ individuals in Uganda received neurologic, neuropsychological, and functional assessments; began HAART; and were followed up for 6 months. Twenty-five HIV- individuals received identical clinical assessments and were followed up for 6 months. RESULTS: In HIV+ individuals, there was improvement in verbal memory, motor and psychomotor speed, executive thinking, and verbal fluency. After adjusting for differences in sex, HIV+ individuals demonstrated significant improvement in the Color Trails 2 test (p = 0.025) compared with HIV- individuals. Symptoms of neuropathy developed in 38% of previously asymptomatic HIV+ patients after initiation of the stavudine-based HAART. CONCLUSIONS: After the initiation of highly active antiretroviral therapy (HAART) including stavudine, HIV+ individuals with cognitive impairment improve significantly as demonstrated by improved performance on a test of executive function. However, peripheral neurotoxicity occurred in 30 patients, presumably because of stavudine-based HAART, suggesting the need for less toxic therapy.
BACKGROUND: The frequency of HIV dementia in a recent study of HIV+ individuals at the Infectious Disease Institute in Kampala, Uganda, was 31%. Coformulated generic drugs, which include stavudine, are the most common regimens to treat HIV infection in Uganda and many other parts of Africa. OBJECTIVE: To evaluate the benefits and risks of stavudine-based highly active antiretroviral therapy (HAART) for HIV-associated cognitive impairment and distal sensory neuropathy. The study compared neuropsychological performance changes in HIV+ individuals initiating HAART for 6 months and HIV- individuals receiving no treatment for 6 months. The risk of antiretroviral toxic neuropathy as a result of the initiation of stavudine-based HAART was also examined. METHODS: At baseline, 102 HIV+ individuals in Uganda received neurologic, neuropsychological, and functional assessments; began HAART; and were followed up for 6 months. Twenty-five HIV- individuals received identical clinical assessments and were followed up for 6 months. RESULTS: In HIV+ individuals, there was improvement in verbal memory, motor and psychomotor speed, executive thinking, and verbal fluency. After adjusting for differences in sex, HIV+ individuals demonstrated significant improvement in the Color Trails 2 test (p = 0.025) compared with HIV- individuals. Symptoms of neuropathy developed in 38% of previously asymptomatic HIV+ patients after initiation of the stavudine-based HAART. CONCLUSIONS: After the initiation of highly active antiretroviral therapy (HAART) including stavudine, HIV+ individuals with cognitive impairment improve significantly as demonstrated by improved performance on a test of executive function. However, peripheral neurotoxicity occurred in 30 patients, presumably because of stavudine-based HAART, suggesting the need for less toxic therapy.
Authors: N Sacktor; N Nakasujja; R Skolasky; K Robertson; M Wong; S Musisi; A Ronald; E Katabira Journal: Neurology Date: 2006-07-25 Impact factor: 9.910
Authors: Ned C Sacktor; Matthew Wong; Noeline Nakasujja; Richard L Skolasky; Ola A Selnes; Seggane Musisi; Kevin Robertson; Justin C McArthur; Allan Ronald; Elly Katabira Journal: AIDS Date: 2005-09-02 Impact factor: 4.177
Authors: M Maj; P Satz; R Janssen; M Zaudig; F Starace; L D'Elia; B Sughondhabirom; M Mussa; D Naber; D Ndetei Journal: Arch Gen Psychiatry Date: 1994-01
Authors: S M de la Monte; D H Gabuzda; D D Ho; R H Brown; E T Hedley-Whyte; R T Schooley; M S Hirsch; A K Bhan Journal: Ann Neurol Date: 1988-05 Impact factor: 10.422
Authors: Beau K Nakamoto; Aaron McMurtray; James Davis; Victor Valcour; Michael R Watters; Bruce Shiramizu; Dominic C Chow; Kalpana Kallianpur; Cecilia M Shikuma Journal: AIDS Res Hum Retroviruses Date: 2010-07 Impact factor: 2.205
Authors: Noeline Nakasujja; Richard L Skolasky; Seggane Musisi; Peter Allebeck; Kevin Robertson; Allan Ronald; Elly Katabira; David B Clifford; Ned Sacktor Journal: BMC Psychiatry Date: 2010-06-10 Impact factor: 3.630
Authors: Ned Sacktor; Noeline Nakasujja; Richard L Skolasky; Mona Rezapour; Kevin Robertson; Seggane Musisi; Elly Katabira; Allan Ronald; David B Clifford; Oliver Laeyendecker; Thomas C Quinn Journal: Clin Infect Dis Date: 2009-09-01 Impact factor: 9.079